Advances in Radiotherapy for Glioblastoma and IDH-Mutant High-Grade Astrocytoma: A Biological and Mechanistic Perspective
Year: 2026
Type: article
Abstract: Glioblastoma (GBM) and IDH-mutant high-grade astrocytoma remain therapeutically challenging. Historical GBM chemoradiation trials reported median overall survival of approximately 15–17 months; contemporary outcomes vary with molecular features, patient selection, and additional therapies. The 60 Gy in 30 fractions partial-brain regimen remains the reference standard for fit patients with newly diagnosed GBM. This narrative review examines radiotherapy based on its underlying biology, distinguishing GBM from IDH-mutant astrocytoma under the WHO molecular framework. It links DNA damage, cell-death programs, and radiation-induced immune signaling to the treatment response and DNA repair, stemness, hypoxia, and the microenvironment to resistance. These mechanisms motivate DNA-damage-response inhibitors, molecularly matched radiosensitizers, and immunotherapy combinations. Tumor treating fields are considered as an adjunctive non-ionizing modality. Proton therapy, FLASH, and MRI-guided adaptive radiotherapy are evaluated for their rationale and normal-tissue effects. Neurocognitive injury is discussed alongside the limitations of proposed hippocampal-sparing objectives. Personalization requires molecular selection and mechanism-matched treatment, with the clinical validation of benefits beyond dosimetry or imaging alone.
Source: Cancers
Authors: Fatemeh Fekrmandi, Arnab Chakravarti
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: glioblastoma, radiotherapy, chemoradiotherapy, DNA damage response, radiosensitizers, tumor microenvironment, hypoxia, stemness, tumor treating fields, proton therapy, FLASH radiotherapy, MRI-guided adaptive radiotherapy, normal tissue effects, hippocampal sparing, treatment resistance, combination immunotherapy, personalized radiotherapy
Open Access status: gold
Estimated APC paid: $3,499
OpenAlex ID: W7236793462
